Lv416
740 积分 2023-01-06 加入
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
1天前
已完结
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
4天前
已完结
Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification
6天前
已完结
Top advances of the year: Targeted therapy for lung cancer
7天前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
7天前
已完结
Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
10天前
已完结
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
13天前
已完结
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
13天前
已完结
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
13天前
已完结
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
13天前
已完结
皖公网安备34019202002308
